Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Zweifel

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancerPaul Nathan, Martin Zweifel, Anwar R Padhani, et al.
BMC Cancer|March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 12, 2012
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumorsDan M Patterson, Martin Zweifel, Mark R Middleton, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2012
Phase I trial of combretastatin A4 phosphate (CA4P) in combination with bevacizumab in patients with advanced cancerPaul Nathan, Martin Zweifel, Anwar R Padhani, et al.
BMC Cancer|March 1, 2020
High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08Martin Fehr, Hanne Hawle, Stefanie Hayoz, et al.
Pageof 3